Colorectal Clinical Trials: What is on the Horizon?

References

• Siegel R , MaJ, ZouZ, JemalA. Cancer statistics, 2014. CA Cancer J. Clin.64(1), 9–29 (2014).
   PubMed Web of Science ®Google Scholar
• Siegel R , DesantisC, JemalA. Colorectal cancer statistics, 2014. CA Cancer J. Clin.64(2), 104–117 (2014).
   PubMed Web of Science ®Google Scholar
• American Cancer Society . Colorectal Cancer. www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics.
   Google Scholar
• Tol J , NagtegaalID, PuntCJ. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med.361(1), 98–99 (2009).
   PubMed Web of Science ®Google Scholar
• Loupakis F , CremoliniC, MasiGet al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med.371(17), 1609–1618 (2014).
   PubMed Web of Science ®Google Scholar
• Loupakis F , CremoliniC, LonardiS. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J. Clin. Oncol.32(Suppl. 5s), Abstract 3519 (2014).
   Google Scholar
• Ahmadzadeh M , JohnsonLA, HeemskerkBet al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood114(8), 1537–1544 (2009).
   PubMed Web of Science ®Google Scholar
• Baitsch L , LegatA, BarbaLet al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS ONE7(2), e30852 (2012).
   PubMed Web of Science ®Google Scholar
• Topalian SL , HodiFS, BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med.366(26), 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Brahmer JR , DrakeCG, WollnerIet al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Dolcetti R , VielA, DoglioniCet al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol.154(6), 1805–1813 (1999).
   PubMed Web of Science ®Google Scholar
• Alexander J , WatanabeT, WuTT, RashidA, LiS, HamiltonSR. Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol.158(2), 527–535 (2001).
   PubMed Web of Science ®Google Scholar
• Smyrk TC , WatsonP, KaulK, LynchHT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer91(12), 2417–2422 (2001).
   PubMed Web of Science ®Google Scholar
• Young J , SimmsLA, BidenKGet al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am. J. Pathol.159(6), 2107–2116 (2001).
   PubMed Web of Science ®Google Scholar
• Le DT , UramJN, WangHet al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med.372(26), 2509–2520 (2015).
   PubMed Web of Science ®Google Scholar
• Lutz ER , WuAA, BigelowEet al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res.2(7), 616–631 (2014).
   PubMed Web of Science ®Google Scholar
• Soares KC , RuckiAA, WuAAet al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J. Immunother.38(1), 1–11 (2015).
   PubMed Web of Science ®Google Scholar
• Okuno K , SugiuraF, HidaJIet al. Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp. Ther. Med.2(1), 73–79 (2011).
   PubMed Web of Science ®Google Scholar
• Hazama S , OkaM, YoshidaKet al. Phase I clinical trial of cancer vaccine with five novel epitope peptides with metastatic colorectal cancer (mCRC). J. Clin. Oncol.29(15 Suppl.), 2510 (2011).
   Google Scholar
• Marx AH , BurandtEC, ChoschzickMet al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum. Pathol.41(11), 1577–1585 (2010).
   PubMed Web of Science ®Google Scholar
• Osako T , MiyaharaM, UchinoS, InomataM, KitanoS, KobayashiM. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology55(6), 548–555 (1998).
   PubMed Web of Science ®Google Scholar
• Bodkin DK , NibertML, FieldsBN. Proteolytic digestion of reovirus in the intestinal lumens of neonatal mice. J. Virol.63(11), 4676–4681 (1989).
   PubMed Web of Science ®Google Scholar
• Rosen L , EvansHE, SpickardA. Reovirus infections in human volunteers. Am. J. Hyg.77, 29–37 (1963).
   PubMed Web of Science ®Google Scholar
• Battcock SM , CollierTW, ZuD, HirasawaK. Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J. Virol.80(9), 4422–4430 (2006).
   PubMed Web of Science ®Google Scholar
• Strong JE , CoffeyMC, TangD, SabininP, LeePW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J.17(12), 3351–3362 (1998).
   PubMed Web of Science ®Google Scholar
• Prahallad A , SunC, HuangSet al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature483(7387), 100–103 (2012).
   PubMed Web of Science ®Google Scholar
• Corcoran RB , EbiH, TurkeABet al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov.2(3), 227–235 (2012).
   PubMed Web of Science ®Google Scholar
• Corcoran RB , AtreyaCE, FalchookGSet al. Phase I–II trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitior trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis. J. Clin. Oncol.32(Suppl. 5s), Abstract 3517 (2014).
   Google Scholar
• Misale S , ArenaS, LambaSet al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med.6(224), 224ra226 (2014).
   Web of Science ®Google Scholar
• Troiani T , NapolitanoS, VitaglianoDet al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin. Cancer. Res.20(14), 3775–3786 (2014).
   PubMed Web of Science ®Google Scholar
• Schellens J , Van GeelR, BendellJet al. Final biomarker analysis of the pahse I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. Presented at: The 106th Annual Meeting of the American Association for Cancer Research. Philadelphia, PA, USA, 18–22 April 2015.
   Google Scholar
• Davies H , BignellGR, CoxCet al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Tie J , GibbsP, LiptonLet al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int. J. Cancer128(9), 2075–2084 (2011).
   PubMed Web of Science ®Google Scholar
• Samowitz WS , SweeneyC, HerrickJet al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res.65(14), 6063–6069 (2005).
   PubMed Web of Science ®Google Scholar
• Yokota T , UraT, ShibataNet al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br. J. Cancer104(5), 856–862 (2011).
   PubMed Web of Science ®Google Scholar
• Price TJ , HardinghamJE, LeeCKet al. Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J. Clin. Oncol.29(19), 2675–2682 (2011).
   PubMed Web of Science ®Google Scholar
• Douillard JY , OlinerKS, SienaSet al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med.369(11), 1023–1034 (2013).
   PubMed Web of Science ®Google Scholar
• Morris V , OvermanMJ, JiangZQet al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin. Colorectal Cancer13(3), 164–171 (2014).
   PubMed Web of Science ®Google Scholar
• Tran B , KopetzS, TieJet al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer117(20), 4623–4632 (2011).
   PubMed Web of Science ®Google Scholar
• Sosman JA , KimKB, SchuchterLet al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med.366(8), 707–714 (2012).
   PubMed Web of Science ®Google Scholar
• Flaherty KT , PuzanovI, KimKBet al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9), 809–819 (2010).
   PubMed Web of Science ®Google Scholar
• Falchook GS , LongGV, KurzrockRet al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial. Lancet379(9829), 1893–1901 (2012).
   PubMed Web of Science ®Google Scholar
• Hauschild A , GrobJJ, DemidovLVet al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet380(9839), 358–365 (2012).
   PubMed Web of Science ®Google Scholar
• Kopetz S , DesaiJ, ChanEet al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. doi: 10.1200/JCO.2015.63.2497 (2015) ( Epub ahead of print).
   Google Scholar
• Corcoran RB , Dias-SantagataD, BergethonK, IafrateAJ, SettlemanJ, EngelmanJA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal.3(149), ra84 (2010).
   PubMed Web of Science ®Google Scholar
• Flaherty KT , InfanteJR, DaudAet al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med.367(18), 1694–1703 (2012).
   PubMed Web of Science ®Google Scholar
• Corcoran RB , AtreyaCE, FalchookGSet al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J. Clin. Oncol. doi: 10.1200/JCO.2015.63.2471 (2015) ( Epub ahead of print).
   Google Scholar
• Yaeger R , CercekA, O’reillyEMet al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin. Cancer Res.21(6), 1313–1320 (2015).
   PubMed Web of Science ®Google Scholar
• Hong DS , MorrisVK, FuSet al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J. Clin. Oncol.32(Suppl. 5s), Abstract 3516 (2014).
   Google Scholar
• Tabernero J , ChanE, BaselgaJet al. VE-BASKET, a Simon 2-stage adaptive design, Phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J. Clin. Oncol.32(Suppl. 15s), s217 (2014).
   Google Scholar
• Atreya CE , Van CutsemE, BendellJCet al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J. Clin. Oncol.33(Suppl. 15s), Abstract 103 (2015).
   Google Scholar
• Hurwitz H , FehrenbacherL, NovotnyWet al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D , LangI, MarcuelloEet al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised Phase 3 trial. Lancet Oncol.14(11), 1077–1085 (2013).
   PubMed Web of Science ®Google Scholar
• Tebbutt NC , WilsonK, GebskiVJet al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol.28(19), 3191–3198 (2010).
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP , BatziouC, TrafalisDet al. Treatment of colorectal cancer with and without bevacizumab: a Phase III study. Oncology78(5–6), 376–381 (2010).
   PubMed Web of Science ®Google Scholar
• Saltz LB , ClarkeS, Diaz-RubioEet al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26(12), 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Cunningham D , HumbletY, SienaSet al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Jonker DJ , O’callaghanCJ, KarapetisCSet al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.357(20), 2040–2048 (2007).
   PubMed Web of Science ®Google Scholar
• Karapetis CS , Khambata-FordS, JonkerDJet al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Price TJ , PeetersM, KimTWet al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority Phase 3 study. Lancet Oncol.15(6), 569–579 (2014).
   PubMed Web of Science ®Google Scholar
• Amado RG , WolfM, PeetersMet al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N . Comprehensive molecular characterization of human colon and rectal cancer. Nature487(7407), 330–337 (2012).
   PubMed Web of Science ®Google Scholar
• Aisner DL , NguyenTT, PaskulinDDet al. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol. Cancer Res.12(1), 111–118 (2014).
   PubMed Web of Science ®Google Scholar
• Zeng ZS , WeiserMR, KuntzEet al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett.265(2), 258–269 (2008).
   PubMed Web of Science ®Google Scholar